Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Leukemia

Free Subscription Articles published in Eur J Haematol Retrieve available abstracts of 88 articles: HTML format

Single Articles

June 2025
1. LI Y, Liu X, Li W, Hou L, et al
   Diagnostic and Prognostic Significance of Peripheral Blood RASSF1A, P16, and PTGER4 Gene Methylation in Adult Acute Leukemia.
   Eur J Haematol. 2025 Jun 3. doi: 10.1111/ejh.14442.
   PubMed     Abstract available
   
   
   
2. KRUSZEWSKI M, Schmoor C, Berg T, Rehman UU, et al
   Sensitization of Non-M3 Acute Myeloid Leukemia Blasts to All-Trans Retinoic Acid by the LSD1 Inhibitor Tranylcypromine: TRANSATRA Phase I Study.
   Eur J Haematol. 2025 Jun 3. doi: 10.1111/ejh.14426.
   PubMed     Abstract available
   
   
   
3. TADMOR T, Melamed G, Alapi H, Rokach L, et al
   CLLAF SCORE-A New Risk Score for Predicting Atrial Fibrillation in Treatment-Naive CLL Patients Initiating First- and Second-Generation BTK Inhibitor Therapy.
   Eur J Haematol. 2025;114:1011-1019.
   PubMed     Abstract available
   
   
   May 2025
4. ALNUGHMUSH A, Alyamany R, Remberger M, Pasic I, et al
   Impact of Conditioning Intensity on Survival in Adult Patients (< 65 Years) With Acute Myeloid Leukemia Receiving Antithymocyte Globulin and Post-Transplantation Cyclophosphamide Based GVHD Prophylaxis.
   Eur J Haematol. 2025 May 28. doi: 10.1111/ejh.14438.
   PubMed     Abstract available
   
   
   
5. KOCKEROLS C, Valk PJM, Hogenbirk P, Geelen I, et al
   Treatment-Free Remission Outcomes in a BCR::ABL1 Digital PCR Selected Clinical Cohort of CML Patients.
   Eur J Haematol. 2025;114:900-907.
   PubMed     Abstract available
   
   
   April 2025
6. FRISCH A, Ganzel C, Ofran Y, Krayem B, et al
   Post-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second Remission.
   Eur J Haematol. 2025;114:641-649.
   PubMed     Abstract available
   
   
   March 2025
7. LOHRBERG M, Heber M, Ries L, Markus K, et al
   Dual Targeting of Pim and PI3 Kinases in Mature T-Cell Lymphoma.
   Eur J Haematol. 2025 Mar 31. doi: 10.1111/ejh.14420.
   PubMed     Abstract available
   
   
   
8. CHEN D, Cantu M, Siddon A, Weinberg OK, et al
   TP53-Mutated Acute Myeloid Leukemia and Blast Phase Myeloproliferative Neoplasm: Distinct Mutation Leads to Poorer Prognosis.
   Eur J Haematol. 2025 Mar 28. doi: 10.1111/ejh.14421.
   PubMed     Abstract available
   
   
   
9. POONSOMBUDLERT K, Yodsuwan R, Mott S, Crawford K, et al
   Effect of NPM1 Mutation Subtype and Co-Mutation Patterns on the Outcomes of Acute Myeloid Leukemia.
   Eur J Haematol. 2025 Mar 19. doi: 10.1111/ejh.14415.
   PubMed     Abstract available
   
   
   
10. ZHENG R, Gagan JR, Botten GA, Koduru P, et al
    Genomic Landscape of Mixed Phenotype Acute Leukemia Associated With Immunophenotypic Lineage Predominance: Impact on Diagnosis and Treatment.
    Eur J Haematol. 2025 Mar 18. doi: 10.1111/ejh.14414.
    PubMed     Abstract available
    
    
    
11. CHUNG C, Doan D
    Targeting the Immune Microenvironment in Chronic Lymphocytic Leukemia: An Evolving Therapeutic Strategy.
    Eur J Haematol. 2025 Mar 11. doi: 10.1111/ejh.14408.
    PubMed     Abstract available
    
    
    
12. NAGAFUJI K, Ito Y, Miyamoto T, Eto T, et al
    Clinical Impact of Continuous Dasatinib Administration on the Prognosis of Patients With BCR::ABL1 Acute Lymphoblastic Leukemia: Result of the Prospective MRD2014 Study Conducted by Fukuoka Blood and Marrow Transplantation Group (FBMTG).
    Eur J Haematol. 2025 Mar 7. doi: 10.1111/ejh.14407.
    PubMed     Abstract available
    
    
    
13. BRUZZESE A, Martino EA, Labanca C, Carida G, et al
    Therapeutic Strategies for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies.
    Eur J Haematol. 2025 Mar 6. doi: 10.1111/ejh.14405.
    PubMed     Abstract available
    
    
    
14. GHIMIRE B, Zimmer M, Donthireddy V
    TP53-Mutated Acute Myeloid Leukemia: Review of Treatment and Challenges.
    Eur J Haematol. 2025 Mar 4. doi: 10.1111/ejh.14404.
    PubMed     Abstract available
    
    
    February 2025
15. VEYHE SR, Hansen MH, Cedile O, Moller MB, et al
    A Case-Driven Multi-Omics Analysis for Longitudinal Ibrutinib Response Evaluation of Patients With Chronic Lymphocytic Leukemia.
    Eur J Haematol. 2025 Feb 23. doi: 10.1111/ejh.14397.
    PubMed     Abstract available
    
    
    
16. CASTELLET H, Ramil G, Carricondo M, Onate G, et al
    Measurable Residual Disease in UBTF-TD Adult Acute Myeloid Leukemia.
    Eur J Haematol. 2025 Feb 23. doi: 10.1111/ejh.14402.
    PubMed    
    
    
    
17. ROBAK T, Robak M, Majchrzak A, Krawczynska A, et al
    Atypical Hairy Cell Leukemia-The Current Status and Future Directions.
    Eur J Haematol. 2025 Feb 10. doi: 10.1111/ejh.14388.
    PubMed     Abstract available
    
    
    
18. BENOIT TM, Bachofner A, Wolfensberger N, Zaugg-Berger Y, et al
    Inferior Overall Survival After Haploidentical Donor Lymphocyte Infusions in Relapsed Myeloid Neoplasms.
    Eur J Haematol. 2025;114:315-324.
    PubMed     Abstract available
    
    
    
19. BRESSER H, Schmoor C, Grishina O, Pfeifer D, et al
    Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.
    Eur J Haematol. 2025;114:231-237.
    PubMed     Abstract available
    
    
    January 2025
20. HYPPOLITO JE, Arcuri LJ, Vicente A, Farnese V, et al
    Central Nervous System Involvement in Chronic Lymphocytic Leukemia: A Case-Series.
    Eur J Haematol. 2025 Jan 31. doi: 10.1111/ejh.14389.
    PubMed    
    
    
    
21. YANG MM, Singh R, Haugen M, Duff A, et al
    Adherence to 6-Mercaptopurine (6-MP) and Habit Strength in Pediatric Acute Lymphoblastic Leukemia (ALL).
    Eur J Haematol. 2025 Jan 20. doi: 10.1111/ejh.14386.
    PubMed     Abstract available
    
    
    
22. ZALAPA-SOTO J, Rios-Olais FA, Chacon-Rangel LC, Mora-Canas A, et al
    Hyper-CVAD and Modified CALGB-10403 Regimens in Adult Patients With Philadelphia-Negative Acute Lymphoblastic Leukemia: A Comparative Study.
    Eur J Haematol. 2025 Jan 7. doi: 10.1111/ejh.14381.
    PubMed     Abstract available
    
    
    
23. BRUZZESE A, Martino EA, Labanca C, Mendicino F, et al
    Advances and Challenges in Quizartinib-Based FLT3 Inhibition for Acute Myeloid Leukemia: Mechanisms of Resistance and Prospective Combination Therapies.
    Eur J Haematol. 2025 Jan 6. doi: 10.1111/ejh.14383.
    PubMed     Abstract available
    
    
    
24. BERTON G, Hospital MA, Garciaz S, Rouzaud C, et al
    Outcomes of Elderly Patients Admitted to the Intensive Care Unit for Newly Diagnosed Acute Myeloid Leukemia.
    Eur J Haematol. 2025 Jan 6. doi: 10.1111/ejh.14366.
    PubMed     Abstract available
    
    
    
25. JENSEN ABH, Andersen HRP, Jensen ST, Jensen CF, et al
    Musculoskeletal Symptoms and Misdiagnoses in Children With Acute Myeloid Leukaemia: A Nationwide Cohort Study.
    Eur J Haematol. 2025;114:57-69.
    PubMed     Abstract available
    
    
    December 2024
26. PUCKRIN R, Owen C, Peters A
    Underrepresentation of Small Lymphocytic Lymphoma in Clinical Trials for Chronic Lymphocytic Leukemia.
    Eur J Haematol. 2024 Dec 27. doi: 10.1111/ejh.14376.
    PubMed     Abstract available
    
    
    
27. TANG MW, Van der Tuin D, Aydin M, Heijmans J, et al
    Comparison of HiDAC Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome.
    Eur J Haematol. 2024 Dec 26. doi: 10.1111/ejh.14370.
    PubMed     Abstract available
    
    
    
28. ROWE M, Babushok D, Carroll M, Carulli A, et al
    Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen.
    Eur J Haematol. 2024 Dec 26. doi: 10.1111/ejh.14371.
    PubMed     Abstract available
    
    
    November 2024
29. MORT JF, Brighton D, DiBenedetto S, Wells L, et al
    Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia.
    Eur J Haematol. 2024 Nov 27. doi: 10.1111/ejh.14354.
    PubMed     Abstract available
    
    
    
30. YALNIZ FF, Johnson A, Alnimer Y, Chahine Z, et al
    Unveiling the Genetic and Clinical Differences of Acute Myeloid Leukemia (AML) in Obese Patients.
    Eur J Haematol. 2024 Nov 13. doi: 10.1111/ejh.14338.
    PubMed     Abstract available
    
    
    
31. CHEN EY, Dahlen T, Stenke L, Bjorkholm M, et al
    Loss in Overall and Quality-Adjusted Life Expectancy for Patients With Chronic-Phase Chronic Myeloid Leukemia.
    Eur J Haematol. 2024 Nov 6. doi: 10.1111/ejh.14328.
    PubMed     Abstract available
    
    
    
32. SMITH E, Atenafu EG, Bankar A, Chan S, et al
    Evolution from an antecedent chronic myeloid malignancy does not impact survival outcomes in NPM1-mutated AML.
    Eur J Haematol. 2024;113:716-726.
    PubMed     Abstract available
    
    
    October 2024
33. SHACHAM-ABULAFIA A, Volcheck Y, Ellis M, Shapira S, et al
    Asciminib in Advanced-Line Treatment of Chronic Myeloid Leukemia.
    Eur J Haematol. 2024 Oct 21. doi: 10.1111/ejh.14330.
    PubMed     Abstract available
    
    
    
34. BRUZZESE A, Martino EA, Labanca C, Mendicino F, et al
    Therapy-Related Acute Promyelocytic Leukemia: Case Series and Current Insights.
    Eur J Haematol. 2024 Oct 13. doi: 10.1111/ejh.14327.
    PubMed     Abstract available
    
    
    September 2024
35. MURRAY GF, Bouligny IM, Ho T, Gor J, et al
    Clonal Evolution in 207 Cases of Refractory or Relapsed Acute Myeloid Leukemia.
    Eur J Haematol. 2024 Sep 24. doi: 10.1111/ejh.14308.
    PubMed     Abstract available
    
    
    
36. STEINER N, Massoud R, Richter J, Perekhrestenko T, et al
    Comparable Results Between 8 and 12 Gray TBI in Combination With Fludarabine and Post-Transplant Cyclophosphamide in MRD-Negative but Not in MRD-Positive Acute Lymphoblastic Leukemia Patients Transplanted in First Complete Remission.
    Eur J Haematol. 2024 Sep 19. doi: 10.1111/ejh.14305.
    PubMed     Abstract available
    
    
    
37. BUCELLI C, Capodanno I, Miggiano MC, Cavazzini F, et al
    Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A "Campus CML" Study.
    Eur J Haematol. 2024 Sep 12. doi: 10.1111/ejh.14299.
    PubMed     Abstract available
    
    
    
38. WILLE K, Dumke M, Wilsdorf N, Sadjadian P, et al
    Venetoclax Combined With FLAG-IDA in Refractory or Relapsed Acute Myeloid Leukemia.
    Eur J Haematol. 2024 Sep 9. doi: 10.1111/ejh.14302.
    PubMed     Abstract available
    
    
    
39. ISHIKAWA C, Mori N
    A New Strategy for Adult T-Cell Leukemia Treatment Targeting Glycogen Synthase Kinase-3beta.
    Eur J Haematol. 2024 Sep 6. doi: 10.1111/ejh.14300.
    PubMed     Abstract available
    
    
    
40. LIN S, Liao N, Li X, Yang L, et al
    Prognosis of pediatric BCP-ALL with IKZF1 deletions and impact of intensive chemotherapy: Results of SCCLG-2016 study.
    Eur J Haematol. 2024;113:357-370.
    PubMed     Abstract available
    
    
    August 2024
41. SOUA A, Gilhodes J, Iat A, Hicheri Y, et al
    Venetoclax-based non-intensive induction followed by allogenic stem-cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics.
    Eur J Haematol. 2024 Aug 11. doi: 10.1111/ejh.14290.
    PubMed     Abstract available
    
    
    July 2024
42. RANTI J, Pudas H, Ranta M, Tuominen S, et al
    Treatment and clinical outcomes of patients with acute myeloid leukemia in Finland 2010-2020: A retrospective analysis of electronic health records.
    Eur J Haematol. 2024 Jul 29. doi: 10.1111/ejh.14272.
    PubMed     Abstract available
    
    
    
43. ACKER F, Chromik J, Tiedjen E, Wolf S, et al
    Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy.
    Eur J Haematol. 2024 Jul 18. doi: 10.1111/ejh.14278.
    PubMed     Abstract available
    
    
    
44. KOCKEROLS C, Valk PJM, Janssen JJWM, Hogenbirk P, et al
    Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients.
    Eur J Haematol. 2024 Jul 12. doi: 10.1111/ejh.14271.
    PubMed     Abstract available
    
    
    
45. LINES M, Kemper RM, Wallace J, Alexander T, et al
    Use of allopurinol to manage skewed 6-mercaptopurine metabolism in pediatric maintenance acute lymphoblastic leukemia treatment.
    Eur J Haematol. 2024 Jul 11. doi: 10.1111/ejh.14273.
    PubMed     Abstract available
    
    
    
46. GUEUNING C, Lazaro E, Dupuy H, Leonard C, et al
    Characteristics of large granular lymphocyte leukemia associated with variable common immunodeficiency disorders: A study of 12 cases.
    Eur J Haematol. 2024 Jul 10. doi: 10.1111/ejh.14265.
    PubMed     Abstract available
    
    
    June 2024
47. SKIPPER MT, Birkebaek N, Jensen RB, Rank CU, et al
    Pancreas-related persisting sequelae in ALL survivors with a history of asparaginase-associated pancreatitis: A part of the ALL-STAR study.
    Eur J Haematol. 2024;112:944-956.
    PubMed     Abstract available
    
    
    
48. GERHARDT A, Dorfel S, Schulz H, Schlag R, et al
    Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study.
    Eur J Haematol. 2024;112:927-937.
    PubMed     Abstract available
    
    
    
49. KUTSCH N, Godel P, Voltin CA, Hallek M, et al
    Long-term remission in a patient with relapsed Richter's transformation treated with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell transplantation.
    Eur J Haematol. 2024;112:984-987.
    PubMed     Abstract available
    
    
    May 2024
50. TAGHILOO S, Asgarian-Omran H
    Cross-talk between leukemic and immune cells at the tumor microenvironment in chronic lymphocytic leukemia: An update review.
    Eur J Haematol. 2024 May 2. doi: 10.1111/ejh.14224.
    PubMed     Abstract available
    
    
    
51. KUTSCH N, Giza A, Robrecht S, Stumpf J, et al
    Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.
    Eur J Haematol. 2024 May 1. doi: 10.1111/ejh.14220.
    PubMed     Abstract available
    
    
    April 2024
52. AFTANDILIAN C, Bito XR, Berman D, Zhang A, et al
    Plasma microbial cell-free DNA following chimeric antigen receptor T cell therapy in pediatric patients with relapsed/refractory leukemia.
    Eur J Haematol. 2024 Apr 24. doi: 10.1111/ejh.14216.
    PubMed     Abstract available
    
    
    
53. MARRA JD, Galli E, Giammarco S, Metafuni E, et al
    CAR-T from cord blood in a patient with Ph+ acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplantation.
    Eur J Haematol. 2024 Apr 21. doi: 10.1111/ejh.14217.
    PubMed     Abstract available
    
    
    
54. MIKLOS E, Oliver TP, Adam K, Eva K, et al
    Fix low dose venetoclax-azacitidine treatment of unfit acute myeloid leukemia patients.
    Eur J Haematol. 2024 Apr 21. doi: 10.1111/ejh.14213.
    PubMed     Abstract available
    
    
    
55. GRONLUND JK, Veigaard C, Juhl-Christensen C, Skou AS, et al
    Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning.
    Eur J Haematol. 2024;112:601-610.
    PubMed     Abstract available
    
    
    
56. DELANOTE V, Callens R, Vogelaers D, Deeren D, et al
    Screening for multidrug-resistant organisms in high-risk hospitalized patients with hematologic diseases.
    Eur J Haematol. 2024;112:627-632.
    PubMed     Abstract available
    
    
    
57. PETIT C, Saillard C, Mohty B, Hicheri Y, et al
    Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.
    Eur J Haematol. 2024;112:530-537.
    PubMed     Abstract available
    
    
    
58. ISHIKAWA C, Mori N
    Pivotal role of dihydroorotate dehydrogenase as a therapeutic target in adult T-cell leukemia.
    Eur J Haematol. 2024 Apr 1. doi: 10.1111/ejh.14209.
    PubMed     Abstract available
    
    
    March 2024
59. POONSOMBUDLERT K, Mott S, Miller B, Dhakal P, et al
    Transplant versus no transplant in myelodysplastic syndrome and acute myeloid leukemia with TP53 mutation; a referral center experience.
    Eur J Haematol. 2024 Mar 21. doi: 10.1111/ejh.14199.
    PubMed     Abstract available
    
    
    
60. ZHANG X, Zhang K, Zhang J, Chang W, et al
    DNMTs-mediated SOCS3 methylation promotes the occurrence and development of AML.
    Eur J Haematol. 2024;112:439-449.
    PubMed     Abstract available
    
    
    
61. GARCIA-POUTON N, Ortiz-Maldonado V, Peyrony O, Chumbita M, et al
    Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T-cell therapy.
    Eur J Haematol. 2024;112:371-378.
    PubMed     Abstract available
    
    
    February 2024
62. GAO J, Santana-Santos L, Fu L, Alvey E, et al
    Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/CBFB::MYH11.
    Eur J Haematol. 2024 Feb 22. doi: 10.1111/ejh.14192.
    PubMed     Abstract available
    
    
    
63. SUN Y, Zhu G, Zhong H
    Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC-MRD and treatment guidance for elderly patients.
    Eur J Haematol. 2024 Feb 11. doi: 10.1111/ejh.14187.
    PubMed     Abstract available
    
    
    
64. MELLINGHOFF SC, Robrecht S, Sprute R, Mayer L, et al
    Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia.
    Eur J Haematol. 2024 Feb 4. doi: 10.1111/ejh.14170.
    PubMed     Abstract available
    
    
    
65. INFANTE JB, Esteves GV, Raposo J, de Lacerda JF, et al
    Disseminated intravascular coagulation score evolution in 48 h predicts early death in acute promyelocytic leukemia patients.
    Eur J Haematol. 2024 Feb 2. doi: 10.1111/ejh.14177.
    PubMed     Abstract available
    
    
    
66. SEVOYAN A, Mekinian A, Chermat F, Ades L, et al
    MDS/CMML from resource-limited region: Characteristics and comparison to tertiary reference European center.
    Eur J Haematol. 2024;112:296-300.
    PubMed     Abstract available
    
    
    January 2024
67. WIESEN MHJ, Stemler J, Fietz C, Joisten C, et al
    Quantification of midostaurin in plasma and serum by stable isotope dilution liquid chromatography-tandem mass spectrometry: Application to a cohort of patients with acute myeloid leukemia.
    Eur J Haematol. 2024 Jan 31. doi: 10.1111/ejh.14178.
    PubMed     Abstract available
    
    
    
68. PODGORICA M, Drivet E, Viken JK, Richman A, et al
    Transcriptome analysis of primary adult B-cell lineage acute lymphoblastic leukemia identifies pathogenic variants and gene fusions, and predicts subtypes for in depth molecular diagnosis.
    Eur J Haematol. 2024 Jan 8. doi: 10.1111/ejh.14164.
    PubMed     Abstract available
    
    
    
69. MOYEN TB, Tomaz V, Campregher PV
    Feasibility, accuracy, and usability analysis of MapAML, a first-in-class app for integrated diagnosis in acute myeloid leukemia.
    Eur J Haematol. 2024 Jan 3. doi: 10.1111/ejh.14158.
    PubMed     Abstract available
    
    
    
70. GUPTA S, Kohorst M, Alkhateeb HB
    Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia.
    Eur J Haematol. 2024;112:51-63.
    PubMed     Abstract available
    
    
    
71. WANG XY, Bian MR, Lin GQ, Yu L, et al
    Tandem bispecific CD123/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia.
    Eur J Haematol. 2024;112:83-93.
    PubMed     Abstract available
    
    
    
72. JI Q, Wu X, Zhang Y, Zeng L, et al
    Adverse events and efficacy of second-round CAR-T cell therapy in relapsed pediatric B-ALL.
    Eur J Haematol. 2024;112:75-82.
    PubMed     Abstract available
    
    
    
73. KHAN AN, Asija S, Pendhari J, Purwar R, et al
    CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?
    Eur J Haematol. 2024;112:6-18.
    PubMed     Abstract available
    
    
    December 2023
74. TAMEFUSA K, Ochi M, Ishida H, Shiwaku T, et al
    Delayed diagnostic interval and survival outcomes in pediatric leukemia: A single-center, retrospective study.
    Eur J Haematol. 2023 Dec 28. doi: 10.1111/ejh.14162.
    PubMed     Abstract available
    
    
    
75. MORI T, Osumi T, Kada A, Ohki K, et al
    Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial.
    Eur J Haematol. 2023 Dec 19. doi: 10.1111/ejh.14148.
    PubMed     Abstract available
    
    
    
76. NEUMANN MA, Nieper P, Simon F, Shimabukuro-Vornhagen A, et al
    A diagnostic challenge-First case of chronic lymphatic leukemia-associated necrotizing sweet syndrome.
    Eur J Haematol. 2023 Dec 17. doi: 10.1111/ejh.14153.
    PubMed     Abstract available
    
    
    
77. COSTA A, Carmosino I, Scalzulli E, Minotti C, et al
    Early death risk score in acute promyelocytic leukemia: A retrospective analysis from a monocentric cohort.
    Eur J Haematol. 2023 Dec 14. doi: 10.1111/ejh.14155.
    PubMed    
    
    
    
78. LAGANA A, Pepe S, Scalzulli E, Carmosino I, et al
    One-month qRT-PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission.
    Eur J Haematol. 2023;111:970-972.
    PubMed    
    
    
    November 2023
79. NEVEJAN L, Labarque V, Boeckx N
    Chronic myeloid leukemia (CML) in children and adolescents-Clinicopathological findings.
    Eur J Haematol. 2023 Nov 20. doi: 10.1111/ejh.14137.
    PubMed     Abstract available
    
    
    
80. LEE BJ, Griffin SP, Doh J, Chan A, et al
    HyperCVAD versus pegaspargase-containing regimens for Hispanic adults with newly diagnosed B-cell acute lymphoblastic leukemia.
    Eur J Haematol. 2023 Nov 6. doi: 10.1111/ejh.14125.
    PubMed     Abstract available
    
    
    October 2023
81. SEGHATOL-ESLAMI VC, Cook EW 3rd, Sharafeldin N, Wolfson J, et al
    Adaptive functioning and academic achievement in pediatric survivors of acute lymphoblastic leukemia: Associations with executive functioning, socioeconomic status, and academic support.
    Eur J Haematol. 2023 Oct 5. doi: 10.1111/ejh.14112.
    PubMed     Abstract available
    
    
    
82. KRISTENSEN DT, Brondum RF, Orskov AD, Marcher CW, et al
    Venetoclax-based therapy for relapsed or refractory acute myeloid leukaemia following intensive induction chemotherapy.
    Eur J Haematol. 2023;111:573-582.
    PubMed     Abstract available
    
    
    
83. MIYAJIMA T, Onozawa M, Yoshida S, Miyashita N, et al
    Clinical implications of NUP98::NSD1 fusion at diagnosis in adult FLT3-ITD positive AML.
    Eur J Haematol. 2023;111:620-627.
    PubMed     Abstract available
    
    
    
84. BREINHOLT MF, Schejbel L, Gang AO, Nielsen TH, et al
    Next generation sequencing in routine diagnostics of mature non-Hodgkin's B-cell lymphomas.
    Eur J Haematol. 2023;111:583-591.
    PubMed     Abstract available
    
    
    September 2023
85. AGRAWAL V, Murphy L, Pourhassan H, Pullarkat V, et al
    Optimizing CAR-T cell therapy in adults with B-cell acute lymphoblastic leukemia.
    Eur J Haematol. 2023 Sep 29. doi: 10.1111/ejh.14109.
    PubMed     Abstract available
    
    
    
86. KOCKEROLS C, Valk PJM, Blijlevens NMA, Cornelissen JJ, et al
    BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population.
    Eur J Haematol. 2023 Sep 20. doi: 10.1111/ejh.14107.
    PubMed     Abstract available
    
    
    
87. CHATTERJEE G, Dhende P, Raj S, Shetty V, et al
    15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia/lymphoma: Real-world applicability and challenges.
    Eur J Haematol. 2023 Sep 14. doi: 10.1111/ejh.14102.
    PubMed     Abstract available
    
    
    
88. ZARLING LC, Stevenson PA, Soma LA, Martino CH, et al
    Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia.
    Eur J Haematol. 2023 Sep 5. doi: 10.1111/ejh.14089.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.